carlumab alternate identifier cnto discontinued human recombinant monoclonal antibody type targets human cc chemokine ligand chemoattractant protein carlumab development use treatment oncology immune studied application systemic sclerosis atherosclerosis diabetic nephropathy liver fibrosis type inhibitory binding carlumab hypothesized inhibit angiogenesis consequently modulate tumor cell studies focusing effects carlumab performed vitro cell lines vivo mice humans including phase phase clinical trials evaluating efficacy safety dose requirements drug clinical trials carlumab include studies idiopathic pulmonary castrationresistant metastatic prostate solid carlumab developed janssen biotech prior discontinuation due limited success clinical trials immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikicarlumab